- Home
- PANW vs BMY Comparison
PANW vs BMY Comparison
Compare PANW & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANW
- BMY
- Stock Information
- Founded
- PANW 2005
- BMY 1887
- Country
- PANW United States
- BMY United States
- Employees
- PANW N/A
- BMY N/A
- Industry
- PANW Computer peripheral equipment
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- PANW Technology
- BMY Health Care
- Exchange
- PANW Nasdaq
- BMY Nasdaq
- Market Cap
- PANW 118.8B
- BMY 115.2B
- IPO Year
- PANW 2012
- BMY N/A
- Fundamental
- Price
- PANW $177.11
- BMY $56.30
- Analyst Decision
- PANW Buy
- BMY Hold
- Analyst Count
- PANW 43
- BMY 15
- Target Price
- PANW $201.13
- BMY $56.29
- AVG Volume (30 Days)
- PANW 5.6M
- BMY 10.8M
- Earning Date
- PANW 02-18-2025
- BMY 02-06-2025
- Dividend Yield
- PANW N/A
- BMY 4.41%
- EPS Growth
- PANW 332.61
- BMY N/A
- EPS
- PANW 3.85
- BMY N/A
- Revenue
- PANW $8,288,200,000.00
- BMY $47,435,000,000.00
- Revenue This Year
- PANW $16.28
- BMY $7.22
- Revenue Next Year
- PANW $15.43
- BMY $0.24
- P/E Ratio
- PANW $46.05
- BMY N/A
- Revenue Growth
- PANW 15.00
- BMY 5.56
- 52 Week Low
- PANW $130.05
- BMY $39.35
- 52 Week High
- PANW $207.24
- BMY $61.08
- Technical
- Relative Strength Index (RSI)
- PANW 42.56
- BMY 47.26
- Support Level
- PANW $166.21
- BMY $55.08
- Resistance Level
- PANW $175.24
- BMY $56.74
- Average True Range (ATR)
- PANW 4.63
- BMY 0.99
- MACD
- PANW -0.26
- BMY -0.07
- Stochastic Oscillator
- PANW 52.40
- BMY 41.74
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.